Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

BACKGROUND: Until recently, no effective targeted therapies for FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 inhibitor, gilteritinib, was approved in Japan for patients with FLT3(mut+) R/R AML based on the phase 3 ADMIRAL trial, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosono, Naoko, Yokoyama, Hisayuki, Aotsuka, Nobuyuki, Ando, Kiyoshi, Iida, Hiroatsu, Ishikawa, Takayuki, Usuki, Kensuke, Onozawa, Masahiro, Kizaki, Masahiro, Kubo, Kohmei, Kuroda, Junya, Kobayashi, Yukio, Shimizu, Takayuki, Chiba, Shigeru, Nara, Miho, Hata, Tomoko, Hidaka, Michihiro, Fujiwara, Shin-Ichiro, Maeda, Yoshinobu, Morita, Yasuyoshi, Kusano, Mikiko, Lu, Qiaoyang, Miyawaki, Shuichi, Berrak, Erhan, Hasabou, Nahla, Naoe, Tomoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522999/
https://www.ncbi.nlm.nih.gov/pubmed/34363558
http://dx.doi.org/10.1007/s10147-021-02006-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522999/
https://www.ncbi.nlm.nih.gov/pubmed/34363558
http://dx.doi.org/10.1007/s10147-021-02006-7

Ejemplares similares